LAKE FOREST, Ill., June 17 /PRNewswire-FirstCall/ --
Hospira, Inc. (NYSE: HSP), a global specialty pharmaceutical
and medication delivery company, today announced a further
extension of the tender offer by Discus Acquisition Corporation, a
wholly owned Hospira subsidiary, to purchase all outstanding shares
of the common stock of Javelin Pharmaceuticals, Inc. (NYSE
Amex: JAV).
The offer, which was scheduled to expire at 12:00 midnight,
New York City time, on
June 16, 2010 (the end of the day on
June 16, 2010), has been extended until 12:00 midnight,
New York City time, on
June 30, 2010 (the end of the day on
June 30, 2010), unless extended for a
further period. All other terms and conditions of the tender offer
remain unchanged, including procedures for tendering and
withdrawing shares during the extension of the original offer
period.
As of the close of business on the expiration date of the
current offer period, a total of 51,821,576 Javelin shares
(including 2,299,051 shares tendered pursuant to guaranteed
delivery procedures), representing approximately 79.99 percent of
the outstanding shares of Javelin common stock, had been validly
tendered and not withdrawn.
Additional Information
This press release is for informational purposes only and is
neither an offer to purchase nor a solicitation of an offer to sell
shares of Javelin common stock. Hospira has filed a tender offer
statement on Schedule TO, as amended, with the Securities and
Exchange Commission (the "SEC") containing an offer to purchase,
form of letter of transmittal and other documents relating to the
tender offer and Javelin has filed with the SEC a
Solicitation/Recommendation Statement on Schedule 14D-9, as
amended, with respect to the tender offer. Hospira and Javelin have
mailed these documents to Javelin's stockholders. Javelin
stockholders may obtain a free copy of these documents and other
documents filed by Hospira and Javelin with the SEC at the Web site
maintained by the SEC at www.sec.gov.
In addition, Javelin stockholders may obtain a free copy of
these documents by directing a request to Javelin
Pharmaceuticals, Inc., 125 CambridgePark Drive, Cambridge, MA 02140, Attention: Investor
Relations. INVESTORS AND JAVELIN SECURITY HOLDERS ARE URGED TO READ
THESE DOCUMENTS CAREFULLY IN THEIR ENTIRETY BEFORE MAKING ANY
DECISION WITH RESPECT TO THE TENDER OFFER BECAUSE THEY CONTAIN
IMPORTANT INFORMATION.
None of the information included on any Internet Web site
maintained by Hospira, Javelin or any of their affiliates, or any
other Internet Web site linked to any such Web site, is
incorporated by reference in or otherwise made a part of this press
release.
About Hospira
Hospira, Inc. is a global specialty pharmaceutical and
medication delivery company dedicated to Advancing Wellness™. As
the world leader in specialty generic injectable pharmaceuticals,
Hospira offers one of the broadest portfolios of generic acute-care
and oncology injectables, as well as integrated infusion therapy
and medication management solutions. Through its products, Hospira
helps improve the safety, cost and productivity of patient care.
The company is headquartered in Lake
Forest, Ill., and has approximately 13,500 employees. Learn
more at www.hospira.com.
Forward-Looking Statements
This press release contains forward-looking statements,
including statements regarding Hospira's proposed acquisition of
Javelin. Hospira cautions that these forward-looking statements are
subject to risks and uncertainties that may cause actual results to
differ materially from those indicated in the forward-looking
statements. No assurance can be given that the acquisition
transaction described in this press release will be completed, that
completion of the transaction will not be delayed or that Hospira
will realize the anticipated benefits of the transaction. Economic,
competitive, governmental, legal, technological and other factors
that may affect Hospira's operations and may cause actual results
to be materially different from expectations include the risks,
uncertainties and factors discussed under the headings "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in Hospira's Annual Report on
Form 10-K for the year ended Dec. 31, 2009 and any
subsequent Quarterly Reports on Form 10-Q or Current Reports
on Form 8-K, which are incorporated by reference. Hospira
undertakes no obligation to release publicly any revisions to
forward-looking statements as the result of subsequent events or
developments.
|
|
Hospira
Media
|
Hospira Investors
|
|
Tareta Adams
|
Karen King
|
|
(224) 212-2535
|
(224) 212-2711
|
|
|
|
|
|
Ruth Venning
|
|
|
(224) 212-2774
|
|
|
|
|
|
SOURCE Hospira, Inc.